Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06552260 · ClinicalTrials.gov registry record · Early Phase 1
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
A Early Phase 1 study of Glioblastoma and Brain Tumor, sponsored by Ugonma Chukwueke.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT06552260: Recruiting Early Phase 1 study of Glioblastoma and Brain Tumor, sponsored by Ugonma Chukwueke.
NCT06552260 is a Early Phase 1 study of Glioblastoma and Brain Tumor that is actively recruiting participants, run by Ugonma Chukwueke. The registered enrollment target is 27 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06552260, a Early Phase 1 study of Glioblastoma and Brain Tumor, is actively recruiting participants, sponsored by Ugonma Chukwueke.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Primary Outcome
Data will be summarized using descriptive statistics to compare between participants who received presurgical troriluzole and who did not
Conditions Studied
Interventions
- DRUG Troriluzole
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2027-08-01 |
| Phase | Early Phase 1 |
What NCT06552260 shows while recruiting
NCT06552260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Troriluzole is the first listed.
NCT06552260 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06552260 about?
NCT06552260 is a clinical study titled "A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma". This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
What is the current status of trial NCT06552260?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2025-02-19. Estimated completion is 2027-08-01.
What conditions does trial NCT06552260 study?
This clinical trial studies the following conditions: Glioblastoma, Brain Tumor, Recurrent Glioblastoma.
What interventions are being tested in trial NCT06552260?
The interventions under investigation include: Troriluzole (DRUG).
Who is sponsoring clinical trial NCT06552260?
This trial is sponsored by Ugonma Chukwueke, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06552260 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06552260's enrollment target sits among peer trials
27 135th of 199 higher than 64 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI